. 2014 Mar 11;7:30. doi: 10.1186/1757-2215-7-30

Table 5.

Concentrations of anti-Hsp60 and anti-Hsp65 IgG antibodies in group of women with ovarian cancer depending on treatment phase and in control group

	Phase of antineoplastic treatment		Controls
	Untreated so far	After chemotherapy	n = 80
	n = 72	n = 77	n = 80
Anti-Hsp60 (AU/ml)	89,59 ± 89,99	99,91 ± 158,40	62,42 ± 33,93
(mean ± SD)	89,59 ± 89,99	99,91 ± 158,40	62,42 ± 33,93
% of positive results	28%*	19%	10%
(> 90 percentile for control group)	p = 0.0041	p = 0.1085	10%
Anti-Hsp65 (AU/ml)	80,31 ± 86,71	109,64 ± 226,24	56,35 ± 35,57
(mean ± SD)	80,31 ± 86,71	109,64 ± 226,24	56,35 ± 35,57
% of positive results	19%	22%*	10%
(> 90 percentile for control group)	p = 0.1103	p = 0.0398	10%

*p < 0.05 in group of women with ovarian cancer compared to control group.